scyther5 / iStockphoto.com
The US Court of Appeals for the Federal Circuit confirmed the validity of two patents covering a testosterone replacement therapy on Friday, July 13, in a win for Bayer Pharma and Endo Pharmaceuticals Solutions.
Start a subscription today to access the LSIPR website.
To access the full archive, digital magazines and special reports you will need to take out a paid subscription.
If you have already subscribed please login.
If you have any technical issues please email tech support.
For access to the complete website, archive, and to receive print publications, choose '12 MONTH SUBSCRIPTION'. For a free, two-week trial with full access, select ‘TWO WEEK FREE TRIAL’.
Bayer, Endo, Custopharm, patent invalidation, patent infringement, US Court of Appeals for the Federal Circuit, testosterone, ANDA, new drug
